ONO-4538 Phase I Study - A Single Center, Open Label, Dose Escalation Single Dose, Followed by Multiple Dose Study of ONO-4538, a Fully Human mAb to PD-1, in Patients With Advanced Malignant Solid Tumors
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluation of the safety (adverse event, clinical laboratory test, vital sign measurement, 12-lead electrocardiography, chest X-ray, ECOG performance status)
Up to study completion, every 2 weeks in principle
Yes
Ohyama Yukiya
Study Director
Ono Pharmaceutical Co. Ltd
Japan: Ministry of Health, Labor and Welfare
ONO-4538-01
NCT00836888
January 2009
Name | Location |
---|